Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification

Aims We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR) for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-in-ring (ViR)], and severe mitral annular calcification [valve-in-mitral annular calcification (ViMAC)]. Methods and results From the TMVR multicentre registry, procedural and clinical outcomes of ViV, ViR, and ViMAC were compared according to Mitral Valve Academic Research Consortium (MVARC) criteria. A total of 521 patients with mean Society of Thoracic Surgeons score of 9.0 ± 7.0% underwent TMVR (322 patients with ViV, 141 with ViR, and 58 with ViMAC). Trans-septal access and the Sapien valves were used in 39.5% and 90.0%, respectively. Overall technical success was excellent at 87.1%. However, left ventricular outflow tract obstruction occurred more frequently after ViMAC compared with ViR and ViV (39.7% vs. 5.0% vs. 2.2%; P < 0.001), whereas second valve implantation was more frequent in ViR compared with ViMAC and ViV (12.1% vs. 5.2% vs. 2.5%; P < 0.001). Accordingly, technical success rate was higher after ViV compared with ViR and ViMAC (94.4% vs. 80.9% vs. 62.1%; P < 0.001). Compared with ViMAC and ViV groups, ViR group had more frequent post-procedural mitral regurgitation ≥moderate (18.4% vs. 13.8% vs. 5.6%; P < 0.001) and subsequent paravalvular leak closure (7.8% vs. 0.0% vs. 2.2%; P = 0.006). All-cause mortality was higher after ViMAC compared with ViR and ViV at 30 days (34.5% vs. 9.9% vs. 6.2%; log-rank P < 0.001) and 1 year (62.8% vs. 30.6% vs. 14.0%; log-rank P < 0.001). On multivariable analysis, patients with failed annuloplasty rings and severe MAC were at increased risk of mortality after TMVR [ViR vs. ViV, hazard ratio (HR) 1.99, 95% confidence interval (CI) 1.27-3.12; P = 0.003; ViMAC vs. ViV, HR 5.29, 95% CI 3.29-8.51; P < 0.001]. Conclusion The TMVR provided excellent outcomes for patients with degenerated bioprostheses despite high surgical risk. However, ViR and ViMAC were associated with higher rates of adverse events and mid-term mortality compared with ViV.

[1]  P. Noirhomme,et al.  Re-repair of the failed mitral valve: insights into aetiology and surgical management† , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  B. Iung,et al.  Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience , 2018, European heart journal.

[3]  I. Palacios,et al.  1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification. , 2018, Journal of the American College of Cardiology.

[4]  C. Detter,et al.  Hospital Outcome and Risk Indices of Mortality after redo-mitral valve surgery in Potential Candidates for Transcatheter Procedures: Results From a European Registry. , 2017, Journal of cardiothoracic and vascular anesthesia.

[5]  W. O’Neill,et al.  Short‐term results of alcohol septal ablation as a bail‐out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  M. Baiocchi,et al.  Mechanical or Biologic Prostheses for Aortic‐Valve and Mitral‐Valve Replacement , 2017, The New England journal of medicine.

[7]  Saibal Kar,et al.  Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report. , 2017, Journal of the American College of Cardiology.

[8]  J. Carroll,et al.  2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2017, Journal of the American College of Cardiology.

[9]  S. Markwell,et al.  Outcomes of Early Mitral Valve Reoperation in the Medicare Population. , 2017, The Annals of thoracic surgery.

[10]  R. Hawkins,et al.  Contemporary outcomes in reoperative mitral valve surgery , 2017, Heart.

[11]  Jeroen J. Bax,et al.  Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. , 2017, Journal of the American College of Cardiology.

[12]  W. O’Neill,et al.  Intentional Percutaneous Laceration of the Anterior Mitral Leaflet to Prevent Outflow Obstruction During Transcatheter Mitral Valve Replacement: First-in-Human Experience. , 2017, JACC. Cardiovascular interventions.

[13]  G. Richardt,et al.  Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. , 2017, JACC. Cardiovascular interventions.

[14]  B. Whisenant,et al.  Early Outcomes of Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. , 2017, JACC. Cardiovascular interventions.

[15]  Roxana Mehran,et al.  Prosthetic Heart Valve Thrombosis. , 2016, Journal of the American College of Cardiology.

[16]  B. Whisenant,et al.  Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. , 2016, JACC. Cardiovascular interventions.

[17]  Emilia Bagiella,et al.  Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. , 2016, The New England journal of medicine.

[18]  H. Schaff,et al.  Effect of Recurrent Mitral Regurgitation Following Degenerative Mitral Valve Repair: Long-Term Analysis of Competing Outcomes. , 2016, Journal of the American College of Cardiology.

[19]  Francois Dagenais,et al.  Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. , 2016, The New England journal of medicine.

[20]  R. Puri,et al.  Transcatheter Valve-in-Valve and Valve-in-Ring for Treating Aortic and Mitral Surgical Prosthetic Dysfunction. , 2015, Journal of the American College of Cardiology.

[21]  T. Nazif,et al.  Transcatheter Valve Implantation in Failed Surgically Inserted Bioprosthesis: Review and Practical Guide to Echocardiographic Imaging in Valve-in-Valve Procedures. , 2015, JACC. Cardiovascular imaging.

[22]  G. Filippatos,et al.  Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. , 2015, Journal of the American College of Cardiology.

[23]  R. Lange,et al.  Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. , 2014, Journal of the American College of Cardiology.

[24]  Antonio Colombo,et al.  Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve. , 2014, Journal of the American College of Cardiology.

[25]  D. Wood,et al.  5-year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. , 2013, Journal of the American College of Cardiology.

[26]  S. Chadalavada,et al.  A guide to fluoroscopic identification and design of bioprosthetic valves: A reference for valve‐in‐valve procedure , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[27]  T. Sundt,et al.  Early thrombosis risk in patients with biologic valves in the aortic position. , 2012, The Journal of thoracic and cardiovascular surgery.

[28]  J. Lock,et al.  Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. , 2009, Journal of the American College of Cardiology.

[29]  A. Moritz,et al.  Midterm survival after decalcification of the mitral annulus. , 2009, Annals of Thoracic Surgery.

[30]  Daniel R Wong,et al.  Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients. , 2009, The Journal of thoracic and cardiovascular surgery.

[31]  Lukas Altwegg,et al.  Percutaneous Transarterial Aortic Valve Replacement in Selected High-Risk Patients With Aortic Stenosis , 2007, Circulation.

[32]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.